Christopher Leamon - Jan 5, 2023 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role
Chief Scientific Officer
Signature
/s/Maria Stahl as Attorney-in-Fact for Christopher Leamon
Stock symbol
FUSN
Transactions as of
Jan 5, 2023
Transactions value $
$0
Form type
4
Date filed
1/9/2023, 05:44 AM
Previous filing
Nov 2, 2021
Next filing
Jan 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +250K $0.00 250K Jan 5, 2023 Common Stock 250K $3.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in 48 equal monthly installments beginning on February 5, 2023.